Search - tctmd.com

Displaying 181 - 200 of 409

Sort: Relevancy | Date

News Conference News EAS 2022

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

Few Cardiac Events Seen in College Athletes After COVID-19: ORCCA Registry

Todd Neale

May 20, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

News Daily News

PCI and CABG Are Complementary Options for Left Main CAD, Say Experts

Michael O'Riordan

April 27, 2022

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Daily News

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

Michael O'Riordan

March 15, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Conference News ISC 2022

CHOICE: Intra-arterial tPA Enhances Benefit of Stroke Thrombectomy

Todd Neale

February 11, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Opinion CV Team Dispatch

January 2022 News Roundup

L.A. McKeown

January 01, 2022

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

Todd Neale

December 27, 2021

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Advertisement

Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Dapagliflozin Boosts Health Status Across LVEF Range

Few Cardiac Events Seen in College Athletes After COVID-19: ORCCA Registry

Good News and Bad for High-Intensity Statin Use in ASCVD

PCI and CABG Are Complementary Options for Left Main CAD, Say Experts

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

CHOICE: Intra-arterial tPA Enhances Benefit of Stroke Thrombectomy

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

January 2022 News Roundup

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

British Medical Groups Express Concern About Inclisiran Rollout

Canagliflozin Improves Quality of Life in HF Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content